AdamWaxmanMD

PubMed

• 60 citations
  T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
  Guido Ghilardi, Joseph A Fraietta, James N Gerson, Vivianna M Van Deerlin, Jennifer J D Morrissette
  Nature Medicine. 2024-04-01
• 282 citations
  Racial disparities in incidence and outcome in multiple myeloma: a population-based study
  Adam Waxman, Pamela J. Mink, Susan S. Devesa, William F. Anderson, Brendan M. Weiss
  Blood. 2010-12-16
• 180 citations
  Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.
  Adam Waxman, Suparna C. Clasen, Wei-Ting Hwang, Alfred L. Garfall, Dan T. Vogl
  JAMA Oncology. 2017-12-28

Abstracts/Posters

• Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma
  Adam Waxman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Proteasome inhibitor associated cardiovascular adverse events: A real-world claims based study. 
  2019 ASCO Annual Meeting - 6/1/2019
• Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all